Comment on: Singh AK et al. From Radiation‐Induced Immune Reprogramming to Globally Implementable Radio‐Immunology

Dear Editor,

1.

We read with great interest the recent article by Singh, Sharma, Kumar and Mishra, ‘Immunological Reprogramming by Radiation Therapy: Implications for Precision Cancer Treatment’, published in Immunology [1]. The article provides a timely synthesis of how radiotherapy can reshape tumour immunity through immunogenic cell death, cGAS‐STING activation, dendritic‐cell maturation, cytotoxic T‐cell priming, checkpoint modulation and abscopal effects. Its central value is that it repositions radiotherapy not merely as a local cytotoxic intervention, but as a biologically active immune modulator.

However, the next step for the field should be more ambitious: to convert radiation‐induced immune reprogramming into an implementation‐ready, globally usable framework. Current evidence suggests that radiotherapy can be both immunostimulatory and immunosuppressive, depending on dose, fractionation, tumour burden, irradiated volume, lymphoid exposure, timing of immunotherapy and the baseline immune fitness of the host [2]. This dual biology may partly explain why several radio‐immunotherapy strategies have shown strong mechanistic promise but inconsistent clinical translation [3, 4].

We propose the concept of radiation–immunity readiness as a practical extension of the reviewed article. This framework has five components: first, reporting an ‘immune‐context dose’ that includes fractionation, target volume, circulating lymphocyte risk, nodal irradiation, steroid exposure and timing of immune checkpoint blockade; second, integrating mechanistic biomarkers such as cGAS–STING activation and type I interferon signalling with toxicity surveillance; third, moving beyond single‐marker prediction toward spatial and temporal immune architecture; fourth, validating low‐cost surrogate assays for settings where spatial multi‐omics is not feasible; and fifth, embedding equity and access considerations into trial design from the beginning [5, 6, 7, 8].

This shift is important because spatial and single‐cell studies increasingly show that treatment response is shaped not only by the presence of immune cells, but also by their location, neighbourhood relationships, suppressive myeloid ecosystems and longitudinal remodelling under therapeutic pressure [6, 7]. Yet these technologies remain expensive and unevenly available. Therefore, a globally relevant radio‐immunology pipeline should be tiered: Discovery through spatial multi‐omics, validation through multiplex immunohistochemistry or targeted transcript panels, and implementation through affordable clinical surrogates such as lymphocyte kinetics, neutrophil‐to‐lymphocyte ratio, steroid exposure, radiotherapy field parameters and treatment‐timing variables.

The global‐health dimension should not be treated as secondary. Radiotherapy demand and workforce requirements are projected to increase substantially by 2050, with major implications for low‐ and middle‐resource health systems [8]. If radio‐immunotherapy advances only through technology‐intensive biomarker platforms, it may widen rather than reduce global cancer inequities. Conversely, if immune‐readiness variables are built into routine radiotherapy planning and reporting, precision immunology could become more transportable, scalable and ethically defensible.

We therefore suggest that future studies of radiation‐induced immune reprogramming should report not only tumour response and survival, but also immune‐context dose, lymphocyte‐sparing parameters, timing of systemic therapy, immune‐related toxicity, infection risk and feasibility of biomarker implementation across health‐system settings. Such reporting would help identify which patients require immune activation, which require protection from radiation‐induced immunosuppression and which may benefit from altered fractionation, myeloid modulation, STING‐pathway targeting, or de‐escalation.

In conclusion, the article by Singh and colleagues provides an excellent mechanistic foundation. The next frontier is to develop radio‐immunology as a solution‐oriented discipline that is spatially informed, toxicity‐aware, trial‐ready and globally scalable.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.